ARTICLE | Clinical News
GenVec begins Phase II
April 26, 2000 7:00 AM UTC
GenVec (Gaithersburg, Md.) began a Phase II trial of its Biobypass angiogenic agent to treat severe coronary artery disease. Biobypass gene therapy is comprised of a vector carrying the vascular endot...